ArticleJournal of conservative dentistry and endodontics2026
Novel acemannan-integrated bioceramic for enhancing human dental pulp stem cell viability and transforming growth factor beta-1 release in pulp regeneration.
Article in Journal of conservative dentistry and endodontics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Effect of the combination of Solanesol fromJournal of conservative dentistry and endodontics · 2026Article
- Telomerase-mediated immortalization preserves the anti-inflammatory activity of dental pulp stem cell extracellular vesicles.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Context: Vital pulp therapy (VPT) preserves pulpal vitality by utilising bioactive materials that promote cell survival and regeneration. Calcium phosphate cement (CPC) and calcium sulfate hemihydrate (CSH) are biocompatible and osteoinductive, while acemannan, a polysaccharide from Aloe vera, exhibits immunomodulatory and regenerative properties. Their combination may synergistically enhance pulpal healing. Aims: This study evaluates the effects of a novel acemannan-integrated CPC-CSH (CPC-CSH-Ace) bioceramic on pH, human dental pulp stem cells (hDPSCs) viability, and transforming growth factor beta-1 (TGF-β1) release. Settings and Design: An in vitro experimental study conducted at ProSTEM (Prodia StemCell) Indonesia. Subjects and Methods: CPC and CSH were combined with 3%, 5%, and 10% acemannan to form test group with NeoPutty and EndoCem Mineral Trioxide Aggregate as controls. pH was measured at 3, 24, and 72 h. hDPSCs viability (%) was assessed using MTT assays at 24 and 72 h, and TGF-β1 levels (pg/mL) quantified by Enzyme-Linked Immunosorbent Assay after 7 days. Data were analysed using one-way analysis of variance followed by Tukey's post hoc test (P < 0.05). Results: The CPC-CSH-Ace 3% group showed the highest cell viability at both 24 and 72 h (P < 0.05) and significantly increased TGF-β1 release (P < 0.05). This upregulation of TGF-β1 represents a key biological signal that promotes odontoblast proliferation and reparative odontogenesis - essential processes for successful pulp capping. All CPC-CSH-Ace groups displayed a slightly alkaline pH conducive to proliferation. Conclusions: The CPC-CSH-Ace 3% formulation showed superior bioactivity, indicating its potential as a novel material for VPT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.